Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Yim, S.F.
Right arrow Articles by Haines, C.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yim, S.F.
Right arrow Articles by Haines, C.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 3, 492-494, March 2001
© 2001 European Society of Human Reproduction and Embryology

Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF

S.F. Yim,1, I.H. Lok, L.P. Cheung, C.M. Briton-Jones, T.T.Y. Chiu and C.J. Haines

Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong, SAR, China

Gonadotrophin-releasing hormone (GnRH) analogues improve the outcome of treatment with IVF by increasing the number and quality of oocytes retrieved and by reducing cycle cancellation rates. Whilst short-acting GnRH analogues are most commonly used, depot preparations are now available that are more convenient for patient use. Some studies have reported that pregnancy rates with depot GnRH analogues are similar to those of short-acting preparations, but others have suggested that the more profound down-regulation seen with depot GnRH analogues results in inferior embryo quality. The purpose of this study was to determine whether a lower than conventional dose of a depot GnRH analogue may be more appropriate for use in ovarian stimulation prior to IVF. Sixty patients were randomized to receive either 3.75 mg (conventional dose) or 1.87 mg (low dose) triptorelin prior to ovarian stimulation for IVF. Suppression was measured using serum concentrations of LH measured 2 and 3 weeks after the administration of the GnRH analogues, the dose of gonadotrophin used and the time to resumption of menses. Mean concentrations of LH were 2.2 ± 1.0 and 1.1 ± 0.6 IU/l in the conventional dose group and 3.5 ± 5.5 and 2.7 ± 1.9 IU/l in the low dose group (P < 0.05 at 2 and 3 weeks). There were no significant differences between the doses of gonadotrophins used, the number of oocytes and embryos available and the time to resumption of menses, nor in the pregnancy rates. Although the degree of suppression as measured biochemically was more profound with the conventional dose, this did not affect the IVF outcome. The use of a lower dose therefore appears to be equally effective and could contribute to a reduction in the cost of treatment.

Key words: gonadotrophin-releasing hormone analogue/IVF/pituitary-ovarian axis

1 To whom correspondence should be addressed. E-mail: sfyim{at}cuhk.edu.hk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
L. Safdarian, F. S. Mohammadi, A. Alleyassin, M. Aghahosseini, A. Meysamie, and E. Rahimi
Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916)
Hum. Reprod., September 1, 2007; 22(9): 2449 - 2454.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Isikoglu, S. Ozdem, M. Berkkanoglu, H. Jamal, Z. Senturk, and K. Ozgur
Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles
Hum. Reprod., June 1, 2007; 22(6): 1657 - 1661.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. Dal Prato, A. Borini, G. Coticchio, M. Cattoli, and C. Flamigni
Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study
Hum. Reprod., October 1, 2004; 19(10): 2200 - 2205.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Penarrubia, F. Fabregues, M. Creus, D. Manau, R. Casamitjana, M. Guimera, F. Carmona, J. A. Vanrell, and J. Balasch
LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH
Hum. Reprod., December 1, 2003; 18(12): 2689 - 2697.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. H. Lok, M. T.V. Chan, D. L.W. Chan, L.P. Cheung, C. J. Haines, and P.M. Yuen
A prospective randomized trial comparing patient-controlled sedation using propofol and alfentanil and physician-administered sedation using diazepam and pethidine during transvaginal ultrasound-guided oocyte retrieval
Hum. Reprod., August 1, 2002; 17(8): 2101 - 2106.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.